Aug 2026· Journal of biochemical and molecular toxicology· Vol 40· 0 citations· 64 references
TL;DR
This review retrieved research on the anti‐myocardial fibrotic effects of curcumin and its analogs published in the last decade from English databases, while a small number of references are older.
Abstract
Myocardial fibrosis is a pathological process characterized by the abnormal accumulation of extracellular matrix, forming pathological scars, due to excessive activation of cardiac fibroblasts during injury repair. This process leads to cardiac stiffening, disruption of electrical conduction, and ultimately, cardiac dysfunction. Curcumin effectively reverses myocardial fibrosis by regulating the metabolic network of extracellular matrix synthesis and degradation. Its analogs, through chemical modification to curcumin, retain and even enhance therapeutic activity meanwhile overcoming inherent limitations of natural curcumin. Given the broad therapeutic potential of curcumin and its analogs against myocardial fibrosis, and the fragmented nature of current research in this field, this review retrieved research on the anti‐myocardial fibrotic effects of curcumin and its analogs published in the last decade from English databases, while a small number of references are older. To establish a theoretical basis for advancing the development and application of curcumin and its analogs, this review synthesizes essential information regarding their properties, mechanisms, pharmacological effects, and therapeutic potential.
C cumulative preclinical evidence validates CUR’s therapeutic potential as a natural anti-fibrotic agent in experimental settings, and shows great prospects for developing anti-fibrotic functional foods and clinical therapeutics, yet high-quality human clinical trials are still urgently needed to confirm its real-world...
Ling-Ji Deng, Xiao-Qin Liu, Hao-Yue Feng et al.· Drug Design, Development and...· 0 citations
Future directives necessitate rigorous botanical authentication, pharmacokinetic/pharmacodynamic profiling, and adoption of human-relevant models, such as induced pluripotent stem cell-derived cardiomyocytes, to bridge the bench-to-bedside gap.
Tian-Tian Long, Juncheng Ma, Wei-Jun Hu et al.· International Journal of Mol...· 0 citations
Overall, curcumin represents a biologically plausible multitarget candidate for osteoarthritis, but larger, well-designed, standardized clinical trials incorporating structural and molecular endpoints are required to determine its therapeutic and disease-modifying potential.
This PUF is considered as a potential integrative therapeutic approach for fibrosis-related diseases and for aggressive cancers with fibrosis, and is expected to target both tumour cells and the fibrotic tumour micro-environment, thereby integrating ethnopharmacological knowledge with molecular rationality.
Rithika Thangaraju, N. Kamlesh, M. Shipin et al.· Frontiers in Pharmacology· 0 citations
This review outlines the mechanisms of action, safety, adverse effects, drug interactions, and the application of CUR-related nanocomposite products, thereby providing a foundation for in-depth research on its antifibrotic properties and clinical application.
Ting Luo, Jia Gao, Qing-Zhi Liang et al.· Frontiers in Pharmacology· 0 citations
The present review systematically elaborates on the process of fibrosis, the main mechanisms of ferroptosis and the role of ferroptosis in fibrosis, and elaborates on innovative therapeutic strategies based on regulating the ferroptosis pathway.
Xin-Cheng Feng, Jue Zhang, Qing-Yuan Ma et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.